Inventor · disambiguated record
David Holtzman
Also filed as: HOLTZMAN DAVID · HOLTZMAN DAVID M · HOLTZMAN DAVID MICHAEL
15 granted patents·28 pending applications·270 citations·filing 2000–2024
92Inventor score
Files withUNIV WASHINGTON22UNIV ST LOUIS5WASHINGTON UNIVERSITY ST LOUIS4HOLTZMAN DAVID M3LILLY CO ELI3
Top patents by PatentIndex Score
43 records- 0197US7195761B2Humanized antibodies that sequester abeta peptideUNIV WASHINGTON·Filed 2002·Granted Mar 27, 2007·185 cites·12 claims
- 0291US7892845B2Methods for measuring the metabolism of neurally dervied biomolecules in vivoUNIV ST LOUIS·Filed 2006·Granted Feb 22, 2011·8 cites·22 claims
- 0387US11124562B2Anti-ApoE antibodiesUNIV WASHINGTON·Filed 2017·Granted Sep 21, 2021·3 cites·15 claims
- 0487US8591894B2Humanized antibodies that sequester amyloid beta peptideHOLTZMAN DAVID M·Filed 2010·Granted Nov 26, 2013·12 cites·18 claims
- 0587US8232107B2Methods for measuring the metabolism of neurally derived biomolecules in vivoBATEMAN RANDALL JOHN·Filed 2011·Granted Jul 31, 2012·8 cites·13 claims
- 0684US7892545B2Humanized antibodies that sequester amyloid beta peptideLILLY CO ELI·Filed 2008·Granted Feb 22, 2011·5 cites·24 claims
- 0784US2025145697A1Anti-apoe antibodiesWASHINGTON UNIVERSITY ST LOUIS·Filed 2024·Application pending·0 cites
- 0880US10830775B2Tau kinetic measurementsUNIV WASHINGTON·Filed 2015·Granted Nov 10, 2020·2 cites·19 claims
- 0980US6465195B2Predictive diagnostic for Alzheimer's diseaseUNIV WASHINGTON·Filed 2000·Granted Oct 15, 2002·29 cites·4 claims
- 1077US7771722B2Assay method for alzheimer's diseaseLILLY CO ELI·Filed 2002·Granted Aug 10, 2010·13 cites·28 claims
- 1176US11926660B2Anti-ApoE antibodiesWASHINGTON UNIVERSITY ST LOUIS·Filed 2021·Granted Mar 12, 2024·0 cites·8 claims
- 1274US9834596B2Antibodies to tauUNIV WASHINGTON·Filed 2013·Granted Dec 5, 2017·3 cites·14 claims
- 1370US2014199718A1Methods for measuring the metabolism of neurally derived biomolecules in vivoUNIV WASHINGTON·Filed 2014·Application pending·0 cites
- 1464US2021395349A1Anti-tau constructsUNIV WASHINGTON·Filed 2020·Application pending·0 cites
- 1562US2016139142A1Methods for measuring the metabolism of neurally derived biomolecules in vivoUNIV WASHINGTON·Filed 2015·Application pending·0 cites
- 1661US2021096139A1Tau kinetic measurementsUNIV WASHINGTON·Filed 2020·Application pending·0 cites
- 1760US2012282642A1Methods for measuring the metabolism of neurally derived biomolecules in vivoBATEMAN RANDALL JOHN·Filed 2012·Application pending·0 cites
- 1859US2020207843A1Anti-tau constructsUNIV WASHINGTON·Filed 2020·Application pending·0 cites
- 1959US2011177509A1Risk factors and a therapeutic target for neurodegenerative disordersUNIV WASHINGTON·Filed 2009·Application pending·0 cites
- 2059US2009035298A1Methods to treat alzheimer's disease or other amyloid beta accumulation associated disordersUNIV ST LOUIS·Filed 2008·Application pending·0 cites
- 2158US9453069B2Assay method for Alzheimer's diseaseLILLY CO ELI·Filed 2013·Granted Sep 27, 2016·0 cites·7 claims
- 2257US2025020669A1Methods for detecting neurofilament light chain in plasma and cerebrospinal fluidWASHINGTON UNIVERSITY ST LOUIS·Filed 2022·Application pending·0 cites
- 2356US7015044B2Diagnostic for early stage Alzheimer's diseaseUNIV WASHINGTON·Filed 2002·Granted Mar 21, 2006·2 cites·15 claims
- 2455US2006039906A1Humanized antibodies that sequester abeta peptideHOLTZMAN DAVID M·Filed 2005·Application pending·0 cites
- 2554US12145988B2Anti-TREM-2 agonist antibodiesWASHINGTON UNIVERSITY ST LOUIS·Filed 2019·Granted Nov 19, 2024·0 cites·9 claims
- 2654US2015140672A1Methods for detecting amyloid beta amyloidosisUNIV WASHINGTON·Filed 2014·Application pending·0 cites
- 2754US2014370619A1Methods for diagnosing alzheimer's diseaseUNIV WASHINGTON·Filed 2012·Application pending·0 cites
- 2853US2022064271A1Methods for treating tauopathiesUNIV WASHINGTON·Filed 2021·Application pending·0 cites
- 2952US2009264355A1Methods to treat alzheimer's disease or other disorders mediated by amyloid-beta accumulation in a subjectUNIV ST LOUIS·Filed 2006·Application pending·0 cites
- 3051US8444977B2Assay method for Alzheimer's diseaseHOLTZMAN DAVID M·Filed 2010·Granted May 21, 2013·0 cites·12 claims
- 3151US2018016328A1Anti-tau constructsUNIV WASHINGTON·Filed 2016·Application pending·0 cites
- 3251US2017146557A1Methods of determining amyloid beta turnover in bloodUNIV WASHINGTON·Filed 2017·Application pending·0 cites
- 3349US2009142766A1Methods for measuring the metabolism of cns derived biomolecules in vivoUNIV ST LOUIS·Filed 2008·Application pending·0 cites
- 3449US2016169916A1Method for detecting amyloid beta amyloidosisUNIV WASHINGTON·Filed 2016·Application pending·0 cites
- 3549US2016178646A1Methods for detecting amyloid beta amyloidosisUNIV WASHINGTON·Filed 2016·Application pending·0 cites
- 3645US2009263829A1Alzheimer's disease biomarkers and methods of useUNIV ST LOUIS·Filed 2007·Application pending·0 cites
- 3744US2014037638A1Compositions and methods for treating amyloid plaque associated symptomsHOLTZMAN DAVID·Filed 2011·Application pending·0 cites
- 3844US2016355581A1Compositions and methods for treating amyloid plaque associated symptomsUNIV WASHINGTON·Filed 2016·Application pending·0 cites
- 3943US2018037641A1Antibodies to tauUNIV WASHINGTON·Filed 2017·Application pending·0 cites
- 4043US2013115716A1Methods of determining amyloid beta turnover in bloodBATEMAN RANDALL J·Filed 2011·Application pending·0 cites
- 4141US2009074775A1Use Of Anti-AB Antibody To Treat Traumatic Brain InjuryHOLTZMAN DAVID MICHAEL·Filed 2005·Application pending·0 cites
- 4235US2011143380A1Alzheimer's disease biomarkers and methods of useUNIV WASHINGTON·Filed 2010·Application pending·0 cites
- 4335US2014377319A1Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluidLEUTHARDT ERIC C·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Holtzman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →